Table 3 Best response in each treatment population
From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
| Â | Gefitinib/Erlotinib n (%) | Afatinib n (%) | Osimertinib n (%) |
|---|---|---|---|
Totala | 170 | 52 | 134 |
Best Response | |||
 CR | 17 (10.0) | 5 (9.6) | 5 (3.7) |
 PR | 99 (58.2) | 26 (50.0) | 94 (70.1) |
 SD | 38 (22.4) | 15 (28.8) | 26 (19.4) |
 PD | 16 (9.4) | 6 (11.5) | 9 (6.7) |
ORR | 116 (68.2) | 31 (59.6) | 99 (73.9) |
DCR | 154 (90.6) | 46 (88.5) | 125 (93.3) |